tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
PremiumRatingsBuy Rating for CG Oncology, Inc. Driven by Promising Clinical Data and Strategic Advancements
24d ago
CG Oncology reports Q2 EPS (54c), consensus (44c)
Premium
The Fly
CG Oncology reports Q2 EPS (54c), consensus (44c)
24d ago
Premium
Ratings
Positive Outlook for CG Oncology: Legal Victory and Promising Milestones Drive Buy Rating
1M ago
CG Oncology price target raised to $56 from $52 at Morgan Stanley
PremiumThe FlyCG Oncology price target raised to $56 from $52 at Morgan Stanley
3M ago
Premium
Company Announcements
CG Oncology Holds 2025 Annual Stockholders Meeting
3M ago
Premium
Ratings
Promising Market Position and Investment Opportunity: CG Oncology’s Creto in NMIBC Treatment
3M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100